Novartis (NVS)’ treatment of progressive supranuclear palsy was granted FDA orphan designation, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis downgraded to Hold from Buy at DZ Bank
- VIG vs. VYM vs. VYMI: Which Is Vanguard’s Best Dividend ETF for Reliable Passive Income?
- Novartis breaks ground on biomedical research center in San Diego
- Trump Trade: Argentina says U.S. to cut hundreds of tariffs
- Novartis Earnings Call: Record Margins Amid Generic Wave